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Summary 
A recombinant soluble form of human FcTRII (rsFcTRII)  was genetically engineered by the 
insertion of a termination codon 5' of sequences encoding the transmembrane domain of a human 
FcTRII eDNA. Chinese hamster ovary cells were transfected with the modified cDNA and the 
secreted rsFcTRII purified from the tissue culture supernatant (to >95%, assessed  by SDS-PAGE) 
using heat aggregated human immunoglobulin G (IgG) immunoaffinity chromatography.  The 
IgG-purified rsFcTRII was relatively homogeneous (•31,000  Me) whereas the total unpurified 
rsFcTRII secreted into the tissue culture supernatant  was heterogeneous relating to N-linked 
glycosylation differences. Functional in vitro activity of the rsFcTRII was demonstrated by: (a) 
ability to bind via the Fc portion of human IgG and mouse IgG (IgG2a>IgGl>>IgG2b); (b) 
complete inhibition of binding of erythrocytes sensitized with rabbit IgG to membrane-bound 
FcTRII on K562 cells; and (c) inhibition of the anti-Leu4-induced T  cell proliferation  assay. 
Blood dearance and biodistribution studies show the rsFcTRII was excreted predominantly through 
the kidney in a biphasic manner,  with an or-phase (tl/2 '~25 min) and a r-phase (tl/2 '~4.6 
h);  the kidneys were the only organs noted with tissue-specific accumulation. In vivo,  the 
administration of rsFc~RII significantly inhibited the immune complex-mediated inflammatory 
response induced by the reversed passive Arthus reaction model in rats. There was a specific and 
dose-dependent  relationship between the amount of rsFcTRII administered,  and the reduction 
in the size and severity of the macroscopic inflammatory lesion. Histological analysis of the skin 
showed a diffuse neutrophil infiltrate  in both control and rsFcTRII-treated  rats,  however the 
perivascular infiltrate and the red cell extravasation was less intense in the rsFc~RII-treated  group. 
It is likely that complement activation leads to neutrophil chemotaxis, but neutrophil activation 
via FcyRII, which results in inflammatory mediator release, is inhibited. The data indicate that 
rsFcyRII is a potential therapeutic agent for the treatment of antibody or immune complex-mediated 
tissue damage. 
F 
e receptors for IgG (FcTR) exist in two forms: membrane- 
bound FcTR and soluble FcTR (sFcTR) 1 which circu- 
late in biological fluids. The two forms of Fc~Rs have been 
described in both human and murine systems, and have a cen- 
tral  role  in  the  regulation  of the  immune response  (1). 
Membrane-bound human FcTRs  are widely expressed on 
hemopoietic cells and can be divided into three major classes 
on the basis of their structure and affinity for IgG: FcyRI, 
FcyRII, and FcTRIII (2, 3). FcTRs are important signal trans- 
duction molecules, and the interaction of immune complexes 
1 Abbreviations used in this paper: CHO, Chinese hamster ovary; EA, sheep 
red blood cell sensitized with rabbit IgG; HAGG, heat aggregated human 
lgG; MSX, l.-methionine sulphoxamine; R.PAR, reversed  passive Arthus 
reaction; sFcTR, soluble receptor for the constant region of IgG. 
through the Fc portion of IgG or mAbs with cell surface 
FcTRs triggers the activation of monocytes, neutrophils, and 
platelets (4-15). The binding of immune-complexes to mono- 
cytes and neutrophils stimulates the release of inflammatory 
mediators such as leukotrienes, prostaglandins, and cytokines 
(TNF-a, IL-1, and IL-6), inducing tissue damage (16-22). 
Although the exact role of the Fc~R(s) in mediating each 
of these effects has not been fully determined, human FcTRII 
has been definitively shown to signal immune complex-me- 
diated activation of neutrophils and monocytes. In addition, 
platelets  interact with immune complexes by cell  surface 
FcTRII (the only FcTR expressed on platelets),  leading to 
the secretion of mediators  and platelet  aggregation (8-15). 
Endogenous and recombinant sFcyR have been shown to 
have both in vitro and in vivo immunoregulatory activity 
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are released from cells expressing membrane-bound Fc~rR: 
activated T cells, B cells, macrophages,  monocytes, and gran- 
ulocytes (33-39).  Soluble Fc'yR can be released by proteol- 
ysis of membrane-bound Fc'yR. (28,  29, 33),  or possibly by 
alternative RNA splicing of the transmembrane exon (40), 
and can be stimulated by Ig and cytokines (1). Endogenous 
mouse sFc'yR has a relative molecular mass of 35-40 kD and 
reacts with an anti-mouse Fc'yRII mAb, 2.4G2. This anti- 
genic similarity provides further evidence  that endogenous 
sFcyRII and membrane-bound FcyRII are structurally related 
(41).  In vitro, murine sFc'yRII can modulate the immune 
response by inhibition of four separate pathways: (a) binding 
of immune complexes to cell surface Fc'yRII; (b) Clq binding 
to IgG; (c) B cell growth; and (d) IgG and IgM antibody 
production from B  cells  (1,  23-29).  Endogenous murine 
sFc3,RII  can be detected in serum of normal mice, and is 
elevated in states of altered immunity and tumor-bearing mice, 
indicating it may have an important biological role in vivo 
(36, 42-46).  Supporting this concept, murine recombinant 
sFc'yRII has been demonstrated to inhibit the in vivo IgG 
response in mice (29). Similarly in humans, sFyRIII can be 
detected in vivo from serum of normal individuals and pa- 
tients with autoimmune diseases, and at sites of inflamma- 
tion (47-49). The immunosuppressive properties of sFc3"RII 
and its potential ability to inhibit membrane-bound Fc'yRII- 
mediated cellular activation by immune complexes, opens new 
therapeutic pathways for the treatment of antibody or im- 
mune complex-mediated tissue injury. This study describes 
the production, characterization, in vitro and in vivo activity 
of a human rsFcyRII. 
Materials  and Methods 
Genetic Engineering and Production of rsFcTRIL  Using the PCR, 
cDNA for a truncated soluble form of human Fc3,RII was pro- 
duced by inserting a premature termination codon 5' of the trans- 
membrane domain of a membrane-bound FcyRII cDNA (HFc3.0) 
(50). The HFc3.0 cDNA encodes the Fc3,RIIa allelic variant ex- 
pressing glutamine and histidine at amino acid positions 27 and 
131, respectively. The oligonucleotide primers used in the PCR 
were 5'  oligonucleotide, NR1  (5'TACGAATTCCTATGGAGA- 
CCCAAATGTCTCY), and 3' oligonucleotide, F12 (5'CATTCT- 
AGACTATTGGACAGTGATGGTCAC3'). Both oligonucleotide 
primers were phosphorylated (100 ng primer, 2/zl 10 mM ATP, 
50 mM Tris-HC1, pH 7.6, 10 mM MgCh, 5 mM dithiothreitol, 
0.1 mM EDTA, 80 U polynucleotide kinase [Pharmacia, Uppsala, 
Sweden], in 200/zl, incubated for 1 h at 37~  and used to amplify 
the mutated cDNA (100 ng of membrane-bound Fc'yR.II  cDNA 
HFc3.0, 500 ng of primers, 50 mM KC1, 10 mM Tris-HC1, pH 
8.3, 1.5  mM MgCI2, and 2.5  U  Replinase [Dupont,  Boston, 
MA  D with a 30 cycle PCR. The oligonucleotide F12 converted 
the Va1171 codon to a TAG stop codon in the HFc3.0 amplified 
cDNA,  resulting in a 635-bp blunt-ended nucleotide fragment, 
which was ligated into the Sinai restriction site of the linearized 
dephosphorylated pEE6/HCMWGS eukaryotic expression vector 
(Celltech, Slough, England). The plasmid  construct was transfected 
into Chinese hamster ovary (CHO) cells using the calcium phos- 
phate precipitation method (51, 52) and grown in glutamine-free 
Glasgow's modified  Eagles medium (Flow Laboratories,  Melbourne, 
Australia) with 10% FCS (Commonwealth Serum Laboratories, 
Melbourne, Australia) dialyzed against PBS. The transfected cells 
were sdected with 15-100 #M t-methionine sulphoxamine  (MSX) 
(Sigma Chemical Co., St. Louis, MO) and the supematants from 
surviving  clones were screened  for the presence of rsFcyRII by their 
ability to inhibit the binding of an anti-Fc'yRII mAb, 8.26, to 
Fc'yRII  + K562 cells, and an ELISA using two anti-Fc'yRII mAbs 
(8.26 and 8.7) (53). The level of rsFc~/RII in tissue culture super- 
natant was increased by: (a) gene amplification; clones originally 
selected at 15/zM MSX were further selected 100/zM MSX; and 
(b) growing the transfected CHO cells in the presence of 2 mM 
sodium but) rate. For large scale production, transfected cells were 
grown  in  roller bottles  (850 cm  2,  Becton Dickinson  &  Co., 
Mountain View, CA) seeded at 5  x  107 cells/ml and grown for 
14 d until the cells were detached. 
lmmunoafllnity Purification tithe rsFcTRlI.  Cell culture super- 
natant containing the rsFc3,RII  was passed through a 0.2-#m filter 
and the sample was loaded onto an af~nity column containing heat 
aggregated human IgG (HAGG) coupled to Sepharose 4B beads 
(Pharmacia). To produce this column, 10 mg of HAGG per 1 g 
of CNBr-activated freeze-dried  powder was coupled according to 
the manufacturer's guidelines (Pharmacia). HAGG was prepared 
by heating 6 mg/ml of human IgG (Sandoz, Melbourne, Australia) 
to 63~  for 30 rain. After washing the column with PBS, the bound 
rsFe,/RII was ehted with a 0.1 M acetate  buffer,  pH 4.0, containing 
0.5 M NaC1. The eluant was immediately neutralized with satu- 
rated Tris-HCl and dialyzed against PBS. The molecular weight 
and purity of the rsFc~/RII were determined by SDS-PAGE anal- 
ysis. The protein content of the purified samples was determined 
by absorbance  at 280 nm using an extinction  coefficient  of  el% = 22 
for a 1 mg/ml protein solution calculated  from an amino acid anal- 
ysis of the rsFc3,RII. The purification was carried out at 4~  and 
the purified protein stored frozen at - 70~  in PBS. Samples were 
examined  for the presence of  endotoxin using the Multi-Test  Limulus 
Amebocyte  Lysate  Pyrogent (Whittaker Bioproducts, Walkersville, 
MD). 
Biosynthetic Labeling and Deglycosylation of the rsFcyRiI.  De- 
glycosylated  recombinant protein was produced by adding 5/zg/ml 
tunicamycin  (Sigma  Chemical  Co.) to the secreting  transfected  CHO 
cells for 2 h at 37~  control transfected ceils were grown in the 
absence of tunicamycin.  Both control and tunicamycin-treated  cells 
were pulsed for 2 h with 0.5 mCi of [3SS]methionine and [35S]cys- 
teine (Amersham International, Amersham, UK) in glutamine/me- 
thionine/cysteine free medium  (Select-Amine; GIBCO  BRL, 
Gaithersburg, MD) followed by a 2-h incubation in the presence 
of 100-fold excess cold methionine/cysteine. Metabolically labeled 
supernatants from tunicamycin-treated and untreated transfected 
ceils were precleared for 30 rain at 4~  with packed Sepharose  4B 
beads coupled to protein A (Pharmacia) and immunoprecipitation 
(using 1 ml of radiolabeled supernatant per mAb) carried out for 
1 h at 4~  with 30 #1 of packed Sepharose 4B beads conjugated 
to the following mAbs: (a) anti-Fc3,RII mAbs, 8.26 F(ab'), 8.2 
F(ab')2, 8.7 F(ab')2, IV.3 F(ab'), and CIKM5 F(ab')2, and a con- 
trol mAb, 1705 (5084-4.1) F(ab')2, were used with supernatant 
from transfected ceils grown in the absence of tunicamycin; and 
(b) mAb 8.26 was used to immunoprecipitate from supernatant 
harvested from transfected CHO cells treated with tunicamycin 
(53-56). The beads were washed with a buffer containing PBS, 
1% BSA, I mM PMSF, and 0.1% vol/vol aprotinin, pH 7.4 (Sigma 
Chemical Co.), placed in 20/zl of SDS-PAGE sample buffer (0.1 
M Tris-HC1, pH 7.5, 0.1% SDS, 0.1 M dithiothreitol), boiled for 
5 min, analyzed by SDS-PAGE on a 13% gel which was dried and 
autoradiographed. 
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(100 #g)  was  radiolabeled  with  12sI (Amersham  International) 
using chloramine T (57). The rsF~KII was diluted to 0.2 #g/ml 
in a buffer containing PBS, 1% BSA, 1 mM PMSF, and 0.1% vol/vol 
aprotinin, pH 7.4, precleared,  and immunoprecipitation (0.2/~g 
of labeled rsFc3~RII per antibody) was carried out as described above 
with 30 #1 of packed Sepharose 4B beads conjugated to the fol- 
lowing antibodies:  (a) anti-human Fc~RII mAb, 8.26 F(ab'); (b) 
control  antibody,  1705 F(ab')2, mouse  IgG2a  anti-Ly-12.1;  (c) 
whole mouse IgG1, 1-1 anti-CEA; (d) whole mouse IgG2a 1302 
(49-11.1), anti-Ly-2.1; (e) whole mouse IgG2b 1480 (5041-24.2), 
anti-Ly-6A.2;  (/) whole mouse IgG3, 1308 (49-31.1), anti-Ly-2.1; 
and (g) HAGG (53,  56,  58-60). 
Erythrocytes Sensitized with Rabbit IgG (EAs) Rosetting Inhibition 
Assays.  The ability of the rsFc3/RII to block the binding immune 
complexes to membrane-bound Fc~RII was determined by the in- 
hibition of EA rosette formation. Starting at a final concentration 
of 0.4 mg/ml, doubling dilutions of the purified rsFc~/RII or a 
control protein, OVA, were incubated with 50 #1 of freshly pre- 
pared 2% EA (rabbit anti-sheep red cell polyclonal antibody diluted 
1:50 bound to sheep red cells) for 1 h on ice (61). K562 cells (25 
#1 at 5  x  106 ceils/ml) expressing Fc~cKII were added to the EAs 
and rsFc3,RII,  incubated for 5 rain at 37~  spun at 200 g for 3 
rain, and the pelleted ceils incubated for 30 min on ice. Cells were 
stained with 0.1% ethyl violet and a typical field of 100 cells was 
assessed for rosette formation (at least five red cells or 50% of the 
target cell covered). 
Inhibition of the Anti-Leu4-induced T  Cell Proliferation Assay by 
rsFc'yRII.  In this assay, T  cells coated  with anti-CD3 antibody 
can be cross-linked via the Fc portion, by the Fc'yR on monocytes 
(62, 63). This phenomenon can be inhibited by rsF3~RII. PBMC 
from an individual were isolated using a Ficoll density gradient 
(Pharmacia),  harvested,  washed,  and resuspended  in RPMI 1640 
(Flow Laboratories) supplemented with 10% heat inactivated FCS, 
100 U/ml penicillin,  100/~g/ml streptomycin, 2 mM glutamine 
(Commonwealth Serum Laboratories) and 0.05 mM 2-ME (Kock- 
Light Ltd., Suffolk,  UK) at 5  x  106 cells/ml.  Cells (100/A vol) 
were aliquoted into U-bottomed sterile 96-well microtiter plates 
(Nunc, Roskilde, Denmark) and incubated with 50/A of anti-Leu4 
(Becton Dickinson & Co., Mountain View, CA) at 1:1,000 dilu- 
tion and 50 #1 of  serially diluted rsFc~RII or control protein, OVA, 
starting at 1.0 mg/ml final concentration. Incubation was carried 
out for 72 h at 37~  and over the last 14 h cells were pulsed with 
1 /zCi/well  [~H]tbymidine  (3,000  Ci/mol,  Amersham Interna- 
tional). Cells were harvested onto glass paper discs and incorpora- 
tion of [3H]thymidine  measured by liquid scintillation counting. 
It should be noted that the anti-CD3 (murine IgG1)-induced T 
cell response  is characterized  by a polymorphism with high and 
low responses  (62,  63).  A high response  individual was used in 
this study. 
Blood Clearance  and Biodistn'bution Studies in Mice.  BALB/c mice 
were used to estimate the in vivo half-Life  of the rsFc3tKII and the 
tissue distribution after an intravenous dose. Purified rsFc3/KII (100 
#g) was radiolabeled with 12sI using chloramine T  (57) and free 
12sI removed using PD-IO sephadex column (Pharmacia) (<5% free 
12sI was present as shown by TCA protein precipitation).  Groups 
of  four mice were injected intravenously with radiolabeled rsFeyKII 
and were subsequently killed at various time points collecting blood, 
urine, and tissues; each sample was measured for radioactivity ex- 
pressed as cpm. For the blood clearance study, the blood volume 
was calculated as 7% of the body weight and the half-life of the 
rsFc3,RII obtained from a logarithmic plot of  percent injected dose 
versus time, where tl/2  =  In 2/gradient (64). Radioactivity in 
the urine was expressed as percent injected dose/ml of urine, and 
the organs as percent  injected dose/gram of tissue. 
Arthus Reaction.  A modified reversed passive Arthus reaction 
(RPAR) model (65) was established  using 4-6-wk-old Sprague- 
Dawley rats (Austin Research Institute) anesthetized with an i.p. 
injection of 1.5-2.0 ml of a 1.9% 2,2,2-tribromoethanol (Aldrich 
Chemical Co., Milwaukee,  WI) solution. The rats were shaved, 
and 5 min after a 5 mg i.v. injection of OVA into the tail vein, 
the back of the rat was injected intradermally with either: (a) 50 
/zl of purified rabbit  IgG anti-OVA (500/zg) with 50/zl of PBS, 
positive  control (after  titration, limiting amounts of rabbit  IgG 
anti-OVA were used to give maximal inhibition, similar to that 
used elsewhere) (66); (b) 50 #1 of purified nonimmune rabbit lgG 
(500/~g) with 50 gil of PBS, specificity control; (c) 50/A of rabbit 
IgG anti-OVA (500 #g) with 50 #1 of rsFc'yRII at varying doses 
(50-500/~g) or control protein KLH (500/~g) (Sigma Chemical 
Co.); or (d) rsFc3,KII alone. 
Rats were examined at 6 h, and macroscopic skin lesions were 
analyzed (blind by independent observers) using two criteria:  (a) 
size of the lesion; the area in mm  2 was calculated by multiplying 
the transverse width in two perpendicular directions; and (b) "total 
score" reflecting the severity of each lesion; a minor score of  0 (nil), 
1 (mild),  2 (moderate),  or 3 (severe) was given for two separate 
parameters (oedema and erythema), and a total score for the lesion 
was assigned by adding the two minor scores. Skin biopsies at in- 
jected sites, taken through the center of the lesion, were fixed in 
10% buffered formalin, stained with hematoxylin-eosin (Depart- 
ment of Pathology, Austin Hospital) and examined for edema, poly- 
morphonuclear, and mononuclear cell infiltrate. 
StatisticalAnalysis.  A statistical comparison of the size and scores 
of the rsFeyKII-treated skin and the controls (PBS and KLH treat- 
ment) was performed by a one-way analysis  of  variance (67); p <0.05 
was considered  significant. 
Results 
Production  and  Purification  of rsFc'fRII.  The  rsFc'yRIl 
cDNA construct was transfected into CHO cells and resulted 
in a soluble recombinant protein that was secreted into the 
cell culture supernatant. Maximally expressing amplified trans- 
fected CHO cells (Clone 1.5) were grown in 100/xM MSX 
and produced 4-8/zg of purified rsFc3/RII per ml of cell cul- 
ture supernatant. Immunoaf~nity purification using human 
IgG Fc binding utilized the natural physiological ligand for 
the receptor and gentle elution conditions enabled maximal 
yield, with minimal loss of Fc binding capacity of the recom- 
binant protein. An eluted sample analyzed by SDS-PAGE is 
shown  (Fig.  1)  and  appears  as a  "o31,000 M~ band consis- 
Figure  1.  Samples  from a typical 
purification  profile  of  the rsFc'yRIl 
subjected  to 13% SDS-PAGE  under 
reducing conditions. The starting 
cell culture (lane I),  the effluent 
from the column (lane 2), and the 
eluted rsFc'yRII  (lane  3) are shown. 
Molecular  weight markers (kD) are 
indicated on the left. 
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tide chain and the extra size from two N-linked carbohy- 
drate structures. The rsFcylklI was >95% pure as analyzed 
by SDS-PAGE.  The stability of the rsFc'yRII in tissue cul- 
ture supernatant was measured by the ELISA for Fc3,RII, 
and showed it was stable  (mAb epitopes intact) at 4,  -20, 
and  -70~  for 6 too. Functional activity of the rsFcyRII, 
demonstrated by inhibition of EA rosette formation, was com- 
pletely stable for at least  1 mo at 4~  (data not shown). 
Structure of the Truncated  FcTRII.  RsFcyRII was degly- 
cosylated to determine the contribution of carbohydrate to 
the heterogeneity. Cell culture supernatant of clone 1.5 CHO 
cells biosynthetically labeled with [3SS]methionine  and cys- 
teine was used for immunoprecipitation and the molecular 
weight of the deglycosylated polypeptide determined after 
growing the transfected CHO cells in tunicamycin. Immu- 
noprecipitation with F(ab') or F(ab')2 fragments of specific 
anti-human Fcq,  RII mAbs demonstrated that the total un- 
purified rsFcylklI in tissue culture supernatant was hetero- 
geneous with  *28,000-36,000  Me  (Fig.  2),  whereas  the 
IgG-purified rsFeyR.lI (Fig. 1) was more homogeneous. How- 
ever, after tunicamycin treatment, a homogeneous ~23,000 
Mr band under reducing conditions (Fig. 2) and m21,000 Mr 
in nonreducing conditions (data not shown) was detected, 
which agrees with the predicted molecular mass of 20,000 
and demonstrated that the heterogeneity of the total rsFc3,RII 
protein was due to heterogeneity within the N-linked carbo- 
hydrate, rather than proteolytic degradation or partial trans- 
lation of the mlkNA. The five mAbs used (IV.3,  CIKM5, 
8.2,  8.7,  and 8.26)  (Fig.  2) previously have been shown to 
divide into four dusters, each duster defining a separate epi- 
tope on the extracellular domains of FeTRII  (53).  Cluster 
1 (8.2 and CIKMS) defines an epitope with determinants in 
Figure 3.  13% SDS-PAGE  analysis  of immunoprecipitated  l~Sl-labeled 
rsFeyRII  under  reducing  conditions  using: mAb 8.26 F(ab  ~ (lane  I); mAb 
1705 F(ab')2 (lane  2); whole murine,  IgG1 mAb 1-1 (lane  3); lgG2a mAb 
1302 (lane  4); IgG2b mAb 1480 (lane  5); IgG3 mAb 1308 (lane  6); and 
HAGG (lane 7). Molecular  weight  markers  (kD) are indicated  on the left. 
both domains 1 and 2 of Fcq,  RII and lies distant from the 
Fc binding region, and clusters 2 (8.26), 3 (W.3), and 4 (8.7) 
detect three additional epitopes contained in the second ex- 
traceUular domain only. All five mAbs recognize the heter- 
ogenous glycosylated 31-kD rsFeyRII protein. Detection of 
the rsFc3,1klI by the mAbs, particularly mAbs from duster 
1 which define a combinatorial epitope, indicates that  the 
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Figure 2.  Immunoprecipitation  of  the glycosylated  and deglycosylated 
rsFeyRII  analyzed  on 13% SDS-PAGE  gel under  reducing  conditions,  with 
molecular weight markers (kD) on the left. Supernatant  from [3sS]me- 
thionine/cysteineqabeled  transfected  CHO cells  were  immunoprecipitated 
using: 1705 F(ab')2 control mAb (lane I),  IV.3 F(ab') mAb (lane 2), 
CIKM5 F(ab')2 mAb (lane  3), 8.2 F(ab')2 mAb (lane  4), 8.7 F(ab')2 mAb 
(lane  5), and 8.26 F(ab')  mAb (lane  6). Immunoprecipitation  from super- 
natant using tumicamycin-treated  secreting  CHO cells, with mAb 8.26 
F(ab') is shown in lane 7. 
B 
.r 
b-- 
"r 
20 
]  10  sFc 
5 
0  ..........  i 
.0001  .o01  .01  .1  1  10 
Concentration  (mg/ml) 
Figure 4.  (A) Inhibition  of  EA rosette  formation  by rsFeyRll  (sFc)  using 
K562 Fc~RII  + target cells; and (B) inhibition of the anti-Leu4-induced 
T cell proliferation  assay  using rsFc~rRII  (sFc) or control  protein (OVA). 
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bound Fc'yRII. Since the ligand-purified rsFcq,  RII was ho- 
mogeneous and functional, in that it was purified by IgG 
aggregates  (Fig.  1), only this material was used for further 
studies. 
IgG Fc Binding by rsFeyRII.  The Fc binding capacity of the 
purified  rsFc3,RII was  examined  by  12sI radiolabding  the 
rsFc'yRII and immunopurification with HAGG or murine 
IgG1, IgG2a, IgG2b, and IgG3 mAbs; mAbs 8.26 FOb'  ) (posi- 
tive control) and F(ab')2 fragments of 1705 (Fc binding spe- 
cificity control) were included (Fig. 3). SDS-PAGE analysis re- 
vealed the same 31-kD protein with the anti-Fcq,  RII mAb 
8.26, murine IgG1, IgG2a, and HAGG. Binding to murine 
IgG2b was variable as no binding was detected using the IgG2b 
mAb, 1480 (Fig. 3), although another murine IgG2b mAb ex- 
hibited some binding (data not shown). There was very little 
binding to IgG3 and no binding to the F(ab')2 fragments of 
the nonreactive control mAb 1705 indicating that the binding 
of the purified rsFcyRII to IgG was specifically through the 
interaction of the Fc portion of IgG with the soluble receptor. 
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Figure  5.  Blood clearance and biodistri- 
bution of 12SI-rsFcyRII.  (A) Blood dear- 
ance  of ~zSI-rsFcq,  KII;  percent  initial  in- 
jected dose is shown on the y-axis and time 
(hours)  on  the  x-axis. (B)  Urine t2sI- 
rsFcl'RII levels, expressed  as percent  ini- 
tial injected  dose/ml of urine,  at  15 min 
(n = 4) and I h (n = 2). (C) Biodistribu- 
tion in various organs showing the percent 
initial injected dose/gram of tissue on the 
y-axis. Error bars, SE. 
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from the membrane-bound human Fc3~KII; rsFcqrKII binds 
murine IgG2a>IgGl>>IgG2b, and IgG3. It should be noted 
that the HFc3.0 eDNA encodes a histidine at position 131 
and poor immunoprecipitation with the murine IgG1 mAb 
seen in Fig. 3 would be expected as this is a "low responder" 
FcyKII (68-70). 
The binding of rsFc3,RII to immune complexes was demon- 
strated  by its ability to inhibit the binding of EAs to cell 
surface Fc'yKII. Incubation of EAs with rsFeyKII completely 
inhibited the formation of EA rosettes with K562 cells, with 
a 50% inhibitory final concentration of 20 #g/ml of purified 
rsFc3,KII (Fig. 4 A). In addition, rsFcyRII inhibited the anti- 
Leu4-induced T cell proliferation assay by 50% at a final con- 
centration of 125/zg/ml, indicating the soluble receptor has 
the capacity to block the binding of immune complexes to 
Fc3,KII on peripheral blood monocytes (Fig. 4 B). We also 
tested the ability of rsEc'yRII to inhibit an antibody-dependent, 
cell-mediated cytotoxicity assay and a C'-mediated cell lysis 
assay using rabbit C' and a murine mAb. No inhibition was 
observed  in either assay (data not shown). 
In summary, the physical and functional characteristics of 
the rsFc3,RII  are similar to membrane-bound Fc'yKII:  (a) 
rsPc3,RII is structurally related to membrane-bound Fc3,gII 
as indicated by intact epitopes for the binding of mAbs to 
membrane-bound Fc3'KII;  and  (b)  rsFc3,KII  binds  IgG 
through its Fc region, although the murine isotope binding 
specificity has been altered compared to membrane-bound 
human Fc'yKII. It is noteworthy that the general character- 
istics of human Fc'yKII in relation to binding specificities 
of IgG have been derived from studies using few cell types 
and may not apply in all cases (2). 
Blood Clearance and Biodistribution of rsFcT/RII.  The in vivo 
characteristics of rsFc'yKII were studied in mice by analyzing 
the blood clearance and biodistribution of intravenously ad- 
ministered t2SI-rsFcTRII. The blood clearance studies dem- 
onstrate that t2SI-rsFcTRII is rapidly eliminated from the cir- 
culation in a biphasic manner with an or-phase tl/2 of 25 
min and a/~-phase tl/2 of 4.6 h; after 24 h the 125I-rsFc3,KII 
was totally eliminated (Fig. 5 A). Groups of four mice were 
also injected intravenously and various organs were counted 
for radioactivity (Fig. 5 C). There was a rapid early concen- 
tration of 125I-rsFc'yRII in the kidney at  15 rain and 1 h, 
with a subsequent fall at 6 and 24 h. No other organ ex- 
hibited tissue-specific accumulation. The rapid clearance from 
the circulation, associated with high concentrations in the 
kidney, suggested the recombinant protein was excreted pre- 
dominantly through the kidney. Studies of urine demonstrate 
high levels of It~S-rsFc3~RII at 1 h, indicating this to be the 
major route of excretion (Fig. 5 B).  The effect of route of 
administration was studied by giving either an i.p. or i.v. dose 
of l~5I-rsFc'yKII. An identical pattern of rapid blood dear- 
ance was seen with both i.p.  and i.v. injections (data  not 
shown). 
Inhibition of the Arthus Reaction.  Rats given i.v. OVA (5 
mg) followed by intradermal rabbit anti-OVA IgG (500 #g) 
mixed in PBS developed a visible Arthus reaction within 2 h 
of the intradermal injection and at 6 h were characterized 
macroscopically by an erythematous and edematous inflamed 
area of skin measuring 30 mm  2 determined from the width 
of the lesion in two perpendicular transverse directions (Fig. 
6). Histologically, the tissue section from the site of the le- 
sion showed an inflammatory infiltrate of polymorphonuclear 
cells, and to a lesser extent mononuclear cells, particularly 
around venules in the dermis (Fig. 7). Specifidty of the RPAR 
was demonstrated by giving rats i.v. OVA, intradermal rabbit 
IgG, or rsFc3~RII, all given separately to individual rats, or 
nonimmune rabbit IgG intradermally together with i.v. OVA. 
In all cases, the RPAR did not develop (data not shown). 
To test the effect of rsFc~RII, OVA-injected rats were then 
given a constant amount of rabbit anti-OVA IgG (500/~g) 
mixed with rsFcyRII at varying doses (50-500/~g) in a final 
volume of 100 #1 intradermally. When rsFc3/l~II was given 
with the rabbit anti-OVA IgG, a specific and significant dose- 
dependent inhibition of the size (using 500/~g of rsFcqrRII, 
p <0.05) and the score (using 500 and 150 #g of rsFc~RII, 
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Figure  6.  Size (/t) and score (B) of the Arthus lesions are shown on 
the y-axis, using (x-axis): 500/~g of normal rabbit serum (NRS) (n =  7); 
500/~g of anti-OVA with PBS (n  =  27); 500 #g of anti-OVA with 50 
#g of rsFcyKII (sFc) (n  =  6); 500/xg of anti-OVA with 150 #g of sFc 
(n  =  8); 500 #g of anti-OVA with 500 ~g of slc (n  =  14); and 500/~g 
of anti-OVA with 500/~g ofKLH (n =  4). (n) Number of injection sites 
using multiple rats. Error bars represent SE; (*)p <0.05 compared to the 
PBS- and KLH-treated skin. 
1622  Recombinant  Soluble Human Fc3~R.II Figure  7.  Histology of the Arthus reaction in skin, treated with PBS (positive control) 6 h after injection,  showing intense perivascular neutrophit 
infiltrate,  xl00. 
Figure  8.  Histology of the PBS-treated skin  demonstrating a typical perivascuhr  neutrophil  infiltrate with extravasation of erythrocytes,  x400. 
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to PBS- and KLH (irrelevant protein control) -treated lesions 
(Fig.  6).  The results  represent  multiple injections  using a 
number of different rats. Histological sections taken from the 
sites treated with the rsFcTRII mixed with the rabbit anti- 
OVA showed a marked reduction in neutrophil accumula- 
tion, margination, infiltration around venules, and erythro- 
cyte extravasation compared to PBS-treated skin (Figs. 7-9). 
The mild, persistent  neutrophil infiltrate  in the rsFcTRII- 
treated skin is likely to be a consequence of the short tl/2 
of rsFcyRII and C  activation. 
Discussion 
A functional rsFcTRII protein was made by genetically 
deleting the transmembrane and cytoplasmic domains of a 
human FcyRII protein, and using a novel eukaryotic expres- 
sion system in CHO cells, resulted in the secretion of the 
rsFcyRII into the tissue culture supernatant,  enabling subse- 
quent purification. The recombinant glycoprotein was shown 
to have in vitro and in vivo activity. The truncated 31-kD 
recombinant protein containing the two extracellular domains 
of FcyRIIa could bind human, mouse, and rabbit Ig by their 
Fc portions, and completely inhibited the binding of immune 
complexes to cell surface Fc,/RII. The interaction of immune 
complexes with cell surface FcTRII initiates a number of Fc- 
mediated effector mechanisms  including inflammatory re- 
sponses, and therefore, a dassical model of immune complex 
disease (the Arthus reaction) was used to investigate the pos- 
sible in vivo therapeutic  properties  of the human rsFcTRII. 
The RPAR was significantly inhibited by rsFcTRII in a dose- 
dependent manner, with less extensive macroscopic lesions 
and histological  inflammatory cell infiltrates demonstrated 
in treated areas. 
The  first  part  of the  study  addressed  the  problem  of 
producing large quantities  of purified functional rsFc~RII. 
The mammalian expression vector, pEE6/CMV/GS,  was uti- 
lized as it gives high levels of expression (51). In this study, 
all the original clones did not survive in >15/~M MSX, al- 
though amplification  of the initial clones using 100-1,000 
/xM MSX produced survivors in 100/~M MSX, and a four- 
fold increase  in rsFc,/RII production was noted in the amplified 
clones (4-8 mg/liter of supernatant). This could be increased 
by further selection and attention to the culture medium, 
however the production level sufficed for our studies. Kinetic 
studies (data not shown) using supernatant  and cell lysates 
from biosynthetically labeled transfected CHO cells was per- 
formed to exclude the possibility of a defective  secretory mech- 
anism resulting in intraceUular accumulation of rsFc'},KII. 
These studies demonstrated that the synthesized rsFcTKII 
first appeared in the tissue culture supernatant  within 1 h 
of the initial [3SS]methionine/cysteine  pulse and was totally 
secreted in 2 h, with no intraceUular accumulation. 
RsFcyRII is a functional receptor and clearly binds IgG 
Figure 9.  Histology  of rat skin treated with 500/.tg of rsFcyRlI showing reduction in the inflammatory  reaction,  x 100. 
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pared to the native cell surface Fc3,RII.  Membrane-bound 
human Fc3,RIIa  is a low affinity receptor (K~  =  106 M-1) 
for monomeric IgG, and the low responder form binds mu- 
rine  IgG2b>>IgG2a,IgG3  compared to  rsFcyRII  which 
binds murine IgG2a>IgGl>>IgG2b, or IgG3 (Fig. 3). The 
poor binding ofrsFcyKII to murine IgG1 is consistent with 
the "low responder" phenotype which is a genetically deter- 
mined polymorphism resulting in the expression of two al- 
lelic variants which differ in their ability to bind murine IgG1; 
high responders bind murine IgG1 more avidly  than low 
responders (62, 63). Low responder Fc'yRII, like HFc3.0 used 
herein, contains histidine at position 131 whereas high re- 
sponder FcyRII contains arginine in this position (68-70). 
Furthermore, some changes in fine specificity may not be un- 
expected since significant changes in carbohydrate side chains 
from the native receptor could alter the conformation and 
therefore the binding properties, as reported for other receptors 
(71). This may account for the difference in IgG2a and IgG2b 
binding reported here and in the literature.  The absence of 
the transmembrane and cytoplasmic tail may also influence 
structural and functional aspects of the soluble receptor, how- 
ever, the essential properties have been maintained since the 
rsFc'i,  KII binds IgG via the Fc portion and is recognized by 
mAbs which detect conformational changes in cell surface 
Fc3,RII. 
KsFcyKII is a relatively  small polypeptide (31,000 Mr) 
with '025% of its molecular mass attributable to N-linked 
glycosylation. Small molecular weight compounds would be 
expected to be easily filtered through the glomerulus and in- 
deed, the rsFc3,RII  is rapidly cleared from the circulation 
through the kidneys (Fig. 5). One might expect a longer in 
vivo half-life if rsFc3~KII bound to IgG in serum, however 
several factors may influence this interaction: (a) rapid renal 
clearance not allowing the rsFc3,KII-IgG interaction to ap- 
proach equilibrium in serum; and (b) affinity of monomeric 
IgG for rsFc3'RII. The short half-life of the rsFeyRII in vivo 
will clearly limit the use of the protein as a parenterally ad- 
ministered therapeutic agent, but in its present form, could 
be useful for local therapy such as in inflamed  joints in rheu- 
matoid arthritis. The R.PAR model used in this study produced 
a localized area of dermal inflammation and demonstrates that 
rsFeyRII administered concomitantly with anti-OVA anti- 
body significantly reduces  the immune complex-mediated 
tissue damage. Many cytokines with rapid clearance from the 
circulation, resulting in short-lived pharmacological effects, 
have been successfully modified to increase their half-life and 
subsequent potency of the compound in vivo (72-73).  A 
similar approach with the rsFeyKII protein (currently in prog- 
ress) would broaden its therapeutic application to a parenter- 
ally administered reagent. 
In two other reports (66, 74) C' regulating proteins (soluble 
C receptor type I and decay accelerating factor) did not com- 
pletely inhibit the Arthus reaction. In one study, the RPAK 
model used was similar to that used here (66). The persisting 
inflammatory response seen after treatment with the C' regu- 
lators is likely to be due to "unblocked" FcyR-mediated inflam- 
matory response. Similarly, in the study described herein, in- 
hibition of the inflammatory response was  profound but 
incomplete. This probably relates to the short tl/2 and/or 
inability to inhibit C activation. Since both Fc3'R- and C'- 
mediated inflammatory responses are critical  in the patho- 
genesis of immune complex-induced tissue injury, complete 
inhibition of the inflammatory response presumably requires 
inhibition of both pathways.  Studies are currently in prog- 
ress to determine the potency of "combined" therapy. 
The mode of action of rsFeyKII is not clear but could 
be  mediating  the  anti-inflammatory response  by  several 
different mechanisms. One likely site of inhibition is the ac- 
tivation of neutrophils and monocytes with subsequent re- 
lease of inflammatory mediators which is known to be fig- 
naled through the interaction of immune  complexes with cell 
surface FcyRII, and we have shown in this study that rsFcyKII 
completely inhibits the binding of EA immune complexes 
to cell surface Fc3,RII  and furthermore inhibits the anti- 
Leu4-induced T cell proliferation assay which results from 
the binding of rsFc'yRII to the Fc portion of anti-Leu4 bound 
to T cells (Fig. 4). A second possible mechanism is the inter- 
ruption of the C' cascade known to release many inflamma- 
tory proteins (e.g., C5a) which induce chemotaxis and neu- 
trophil activation. Murine soluble FcyRII has been shown 
to inhibit C'-mediated lysis of SRBC by IgG in vitro (24). 
We found that rsFeyKII did not inhibit C'-mediated cell lysis 
or antibody-dependent cell-mediated killing by mononudear 
cells. Antibody-dependent cell-mediated lysis is a function 
of Fc"/RIII, and therefore inhibition by rsFc'lrRII was not 
expected. It is likely that complement is activated, which leads 
to neutrophil chemotaxis, but neutrophil activation via Fc3,R.II 
by immune complexes, which results in inflammatory medi- 
ator release, is inhibited. Platelets  have been shown to ini- 
tiate or augment immunologically mediated inflammation 
and tissue  injury by the activation of circulating platelets 
through the interaction of immune complexes with cell sur- 
face Fc3,RII (8). Inhibition of platelet activation and aggre- 
gation could also reduce the inflammatory response, and we 
are currently investigating the role of rsFc3,KII in modifying 
platelet function. 
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